Farther Finance Advisors LLC Buys 222 Shares of Chemed Corporation $CHE

Farther Finance Advisors LLC grew its stake in shares of Chemed Corporation (NYSE:CHE) by 148.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 372 shares of the company’s stock after acquiring an additional 222 shares during the quarter. Farther Finance Advisors LLC’s holdings in Chemed were worth $181,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bessemer Group Inc. increased its holdings in shares of Chemed by 14.2% during the first quarter. Bessemer Group Inc. now owns 950 shares of the company’s stock valued at $585,000 after acquiring an additional 118 shares in the last quarter. DAVENPORT & Co LLC bought a new stake in Chemed in the 1st quarter worth about $265,000. Jump Financial LLC bought a new stake in Chemed in the 1st quarter worth about $2,777,000. Mather Group LLC. increased its holdings in Chemed by 53.3% in the 1st quarter. Mather Group LLC. now owns 161 shares of the company’s stock worth $99,000 after buying an additional 56 shares in the last quarter. Finally, Park Place Capital Corp increased its holdings in Chemed by 71.2% in the 1st quarter. Park Place Capital Corp now owns 3,572 shares of the company’s stock worth $2,198,000 after buying an additional 1,486 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of Chemed stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the transaction, the chief executive officer directly owned 96,197 shares of the company’s stock, valued at $44,373,752.16. The trade was a 3.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nicholas Michael Westfall sold 10,012 shares of Chemed stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $421.91, for a total value of $4,224,162.92. The disclosure for this sale can be found here. Insiders sold 13,162 shares of company stock valued at $5,677,511 in the last 90 days. Corporate insiders own 3.29% of the company’s stock.

Chemed Trading Down 1.7%

CHE opened at $440.06 on Thursday. The company has a market cap of $6.41 billion, a price-to-earnings ratio of 22.63, a PEG ratio of 2.61 and a beta of 0.43. The company’s 50 day moving average is $449.68 and its 200 day moving average is $518.69. Chemed Corporation has a 12-month low of $408.42 and a 12-month high of $623.60.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). Chemed had a net margin of 11.56% and a return on equity of 25.83%. The company had revenue of $618.80 million for the quarter, compared to analysts’ expectations of $650.60 million. During the same period in the previous year, the firm earned $5.47 earnings per share. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, analysts predict that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 11th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Monday, August 11th. This is an increase from Chemed’s previous quarterly dividend of $0.50. Chemed’s payout ratio is presently 12.34%.

Analyst Ratings Changes

Several research firms recently commented on CHE. Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. Royal Bank Of Canada reduced their price objective on Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Bank of America reduced their price objective on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Finally, Oppenheimer reduced their price objective on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $578.50.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.